Ruperto N et al. (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372: 383–391
Methotrexate, a DMARD used to treat rheumatoid arthritis, is also suitable for treating patients with juvenile idiopathic arthritis (JIA). Children who fail to respond to methotrexate can be treated with anti-tumor necrosis factor, although some do not respond or are intolerant to this line of therapy. Studies have shown that, in adults with rheumatoid arthritis, treatment with abatacept, a selective T-cell inhibitor, improves the condition. Ruperto and colleagues, therefore, investigated the effects of abatacept in children with JIA refractory to standard treatment.
Patients with JIA (n = 190, aged 6–17 years), recruited from medical centers in Europe, Latin America and the USA, received five doses of 10 mg/kg abatacept (30 min intravenous infusion) during an open-label period of 4 months. Those who responded positively were randomly assigned to receive either further treatment with abatacept (n = 60) or placebo (n = 62) at the point of randomization and every 28 days thereafter for 6 months, or until a disease flare-up. More patients in the abatacept group had improved by at least 50% compared with controls (77% vs 52%, P = 0.0071). More flare-ups occurred in patients who were given placebo than in those who received abatacept (53% vs 20%, P = 0.0003). There was no significant difference in adverse events between the two groups. The authors noted that clinical improvements during the open-label treatment were maintained in many patients randomly assigned to receive placebo.
These results suggest that abatacept therapy is a suitable alternative for children with JIA who fail to respond or have intolerance to DMARDs.
Rights and permissions
About this article
Cite this article
Abatacept therapy in patients with JIA refractory to standard treatment. Nat Rev Rheumatol 4, 506 (2008). https://doi.org/10.1038/ncprheum0888
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0888